Herz

, Volume 39, Issue 1, pp 15–24 | Cite as

Medikamentöse Therapie von Herz- und Lungenerkrankungen

Effekte auf das jeweils andere Organ
  • S. Möhlenkamp
  • G. Weinreich
  • T. Neumann
  • T. Voshaar
  • H. Teschler
Schwerpunkt
  • 264 Downloads

Zusammenfassung

Viele Patienten sind gleichzeitig herz- und lungenkrank. Die Wahl der medikamentösen Therapie richtet sich nicht nur nach der klinischen und prognostischen Wirksamkeit am Zielorgan, sondern auch nach den Effekten am jeweils anderen Organ. Betablockern und Statinen werden sowohl günstige wie auch potenziell ungünstige Wirkungen an der Lunge zugeschrieben. ACE-Hemmer und Amiodaron gehen recht häufig mit pneumologischen Komplikationen einher. Niedrig dosierte Thiaziddiuretika und Kalziumantagonisten werden zur Therapie hypertensiver Asthmatiker empfohlen. Betablocker sollten hier vermieden werden. Theophyllin sollte bei kardial vorerkrankten Patienten nur mit Zurückhaltung verordnet werden. Glukokortikosteroide können kardiovaskuläre Symptome verursachen, während der Phosphodiesterase-4-Hemmer Roflumilast keine ungünstigen kardiovaskulären Wirkungen zu haben scheint. Für Anticholinergika sind günstige wie ungünstige Effekte auf das Herz-Kreislauf-System beschrieben. Insbesondere kurz wirksame Beta-2-Sympathomimetika (SABA) und Makrolide können Herzrhythmusstörungen triggern, und für einige SABA wird eine erhöhte Herzinfarktrate berichtet. Das Wissen um die Wirkungen der für pneumologische und kardiovaskuläre Erkrankungen notwendigen Medikamente am jeweils anderen Organ und um die damit verbundenen Komplikationen und Langzeitwirkungen ist notwendig, um die vielen gleichzeitig herz- und lungenkranken Patienten optimal zu therapieren.

Schlüsselwörter

Herzkrankheiten Lungenkrankheiten Medikamentöse Therapie Komplikationen 

Medical therapy of heart and lung diseases

Effects on the respective other organ

Abstract

Many patients suffer from both heart and lung diseases. The choice of medical drugs should not only be driven by the clinical and prognostic effects on the target organ but should also be selected based on the effects on the respective other organ. Beta blockers and statins have both beneficial and harmful effects on the respiratory system. Angiotensin-converting enzyme (ACE) inhibitors and amiodarone can cause severe lung damage. Low-dose thiazides and calcium antagonists are first-line medications in hypertensive asthma patients but beta blockers should be avoided. Theophyline should be used with caution in patients with known cardiac disease. Glucocorticosteroids can cause cardiovascular symptoms while the phosphodiesterase inhibitor roflumilast appears to have no relevant cardiovascular side effects. Anticholinergic drugs have both favorable and unfavorable cardiovascular (side) effects. Short-acting beta-2 sympathomimetic drugs (SABA) and macrolides in particular can trigger arrhythmia and some SABAs are associated with a higher incidence of myocardial infarction. Detailed knowledge of the effects of drugs used for the treatment of lung and heart diseases on the respective other organ and the associated complications and long-term effects are essential in providing optimal medical care to the many patients who present with both respiratory and cardiovascular diseases.

Keywords

Heart diseases Lung diseases Drug therapy Complications 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt. S. Möhlenkamp, G. Weinreich, T. Neumann, T. Voshaar und H. Teschler geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Albert RK, Connett J, Bailey WC et al (2011) COPD clinical research network. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 365:689–698PubMedCentralCrossRefPubMedGoogle Scholar
  2. 2.
    Alexeeff SE, Litonjua AA, Sparrow D et al (2007) Statin use reduces decline in lung function: VA Normative Aging Study. Am J Respir Crit Care Med 176:742–747PubMedCentralCrossRefPubMedGoogle Scholar
  3. 3.
    Au DH, Udris EM, Fan VS et al (2003) Risk of mortality and heart failure exacerbations associated with inhaled beta-adrenoceptor agonists among patients with known left ventricular systolic dysfunction. Chest 123:1964–1969CrossRefPubMedGoogle Scholar
  4. 4.
    Au DH, Bryson CL, Fan VS et al (2004) Betablockers as single-agent therapy for hypertension and the risk of mortality among patients with chronic obstructive pulmonary disease. Am J Med 117:925–931CrossRefPubMedGoogle Scholar
  5. 5.
    Ann Twiss M, Harman E, Chesrown S, Hendeles L (2002) Efficacy of calcium channel blockers as maintenance therapy for asthma. Br J Clin Pharmacol 53:243–249CrossRefGoogle Scholar
  6. 6.
    Anthonisen NR, Connett JE, Enright PL et al (2002) Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 166:333–339CrossRefPubMedGoogle Scholar
  7. 7.
    Azzam I, Tov N, Elias N, Naschitz JE (2006) Amiodarone toxicity presenting as pulmonary mass and peripheral neuropathy: the continuing diagnostic challenge. Postgrad Med J 82:73–75PubMedCentralCrossRefPubMedGoogle Scholar
  8. 8.
    Barnes PJ (1985) Clinical studies with calcium antagonists in asthma. Br J Clin Pharmacol 20(Suppl 2):289S–298SPubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Barnett MJ, Milavetz G, Kaboli PJ (2005) beta-Blocker therapy in veterans with asthma or chronic obstructive pulmonary disease. Pharmacotherapy 25:1550–1559CrossRefPubMedGoogle Scholar
  10. 10.
    Bateman E, Singh D, Smith D et al (2010) Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies. Int J Chron Obstruct Pulmon Dis 5:197–208PubMedCentralPubMedGoogle Scholar
  11. 11.
    Bear R, Goldstein M, Phillipson E et al (1977) Effect of metabolic alkalosis on respiratory function in patients with chronic obstructive lung disease. Can Med Assoc J 117:900–903PubMedCentralPubMedGoogle Scholar
  12. 12.
    Belchikov YG, Koenig SJ, Dipasquale EM (2013) Potential role of endogenous adenosine in ticagrelor-induced dyspnea. Pharmacotherapy 33(8):882–887CrossRefPubMedGoogle Scholar
  13. 13.
    Benard A, Melloni B, Gosselin B et al (1996) Perindopril-associated pneumonitis. Eur Respir J 9:1314–1316CrossRefPubMedGoogle Scholar
  14. 14.
    Blamoun AI, Batty GN, DeBari VA et al (2008) Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study. Int J Clin Pract 62:1373–1378CrossRefPubMedGoogle Scholar
  15. 15.
    Boulet LP, Milot J, Lampron N, Lacourcière Y (1989) Pulmonary function and airway responsiveness during long-term therapy with captopril. JAMA 261:413–416CrossRefPubMedGoogle Scholar
  16. 16.
    Bucknall CE, Neilly JB, Carter R et al (1988) Bronchial hyperreactivity in patients who cough after receiving angiotensin converting enzyme inhibitors. Br Med J (Clin Res Ed) 296:86–88CrossRefGoogle Scholar
  17. 17.
    Butler K, Maya J, Teng R (2013) Effect of ticagrelor on pulmonary function in healthy elderly volunteers and asthma or chronic obstructive pulmonary disease patients. Curr Med Res Opin 29:569–577CrossRefPubMedGoogle Scholar
  18. 18.
    Campbell SC, Criner GJ, Levine BE et al (2007) Cardiac safety of formoterol 12 microg twice daily in patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther 20:571–579CrossRefPubMedGoogle Scholar
  19. 19.
    Calverley PM, Anderson JA, Celli B et al (2007) Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356:775–789CrossRefPubMedGoogle Scholar
  20. 20.
    Camus P, Lombard JN, Perrichon M et al (1989) Bronchiolitis obliterans organising pneumonia in patients taking acebutolol or amiodarone. Thorax 44:711–715PubMedCentralCrossRefPubMedGoogle Scholar
  21. 21.
    Celli B, Decramer M, Leimer I et al (2010) Cardiovascular safety of tiotropium in patients with COPD. Chest 137:20–30CrossRefPubMedGoogle Scholar
  22. 22.
    Chan ED, King TE (2013) Pulmonary disease induced by cardiovascular drugs. UpToDate. http://www.uptodate.com. Last update: Jan 18, 2013Google Scholar
  23. 23.
    Chan ED, King TE (2013) Amiodarone pulmonary toxicity. UpToDate. http://www.uptodate.com. Last update: Dez 24, 2012 (literature review current through: Sep 2013)Google Scholar
  24. 24.
    Cheng JW (2012) Ticagrelor: oral reversible P2Y(12) receptor antagonist for the management of acute coronary syndromes. Clin Ther 34(6):1209–1220CrossRefPubMedGoogle Scholar
  25. 25.
    Cody RJ Jr, Calabrese LH, Clough JD et al (1979) Development of antinuclear antibodies during acebutolol therapy. Clin Pharmacol Ther 25:800–805PubMedGoogle Scholar
  26. 26.
    Dicpinigaitis PV (2006) Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest 129:169S–173SCrossRefPubMedGoogle Scholar
  27. 27.
    Dean PJ, Groshart KD, Porterfield JG et al (1987) Amiodarone-associated pulmonary toxicity. A clinical and pathologic study of eleven cases. Am J Clin Pathol 87:7–13PubMedGoogle Scholar
  28. 28.
    Dransfield MT, Rowe SM, Johnson JE et al (2008) Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD. Thorax 63:301–305CrossRefPubMedGoogle Scholar
  29. 29.
    Faller M, Quoix E, Popin E et al (1997) Migratory pulmonary infiltrates in a patient treated with sotalol. Eur Respir J 10:2159–2162CrossRefPubMedGoogle Scholar
  30. 30.
    Ferguson GT, Funck-Brentano C, Fischer T et al (2003) Cardiovascular safety of salmeterol in COPD. Chest 123:1817–1824CrossRefPubMedGoogle Scholar
  31. 31.
    Fernandez AB, Karas RH, Alsheikh-Ali AA, Thompson PD (2008) Statins and interstitial lung disease – a systematic review of the literature and of food and drug administration adverse event reports. Chest 134:824–830CrossRefPubMedGoogle Scholar
  32. 32.
    Gottlieb SS, McCarter RJ, Vogel RA (1998) Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 339:489–497CrossRefPubMedGoogle Scholar
  33. 33.
    Hawkins NM, Huang Z, Pieper KS et al (2009) Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Eur J Heart Fail 11(3):292–298PubMedCentralCrossRefPubMedGoogle Scholar
  34. 34.
    Hilleman DE, Malesker MA, Morrow LE, Schuller D (2009) A systematic review of the cardiovascular risk of inhaled anticholinergics in patients with COPD. Int J Chron Obstruct Pulmon Dis 4:253–263PubMedCentralCrossRefPubMedGoogle Scholar
  35. 35.
    Irons BK, Kumar A (2003) Valsartan-induced angioedema. Ann Pharmacother 37:1024–1027CrossRefPubMedGoogle Scholar
  36. 36.
    Israili ZH, Hall WD (1992) Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 117:234–242CrossRefPubMedGoogle Scholar
  37. 37.
    Jensen MT, Kaiser C, Sandsten KE et al (2013) Heart rate at discharge and long-term prognosis following percutaneous coronary intervention in stable and acute coronary syndromes – results from the BASKET PROVE trial. Int J Cardiol 168(4):3802–3806CrossRefPubMedGoogle Scholar
  38. 38.
    Jensen MT, Marott JL, Lange P et al (2013) Resting heart rate is a predictor of mortality in COPD. Eur Respir J 42(2):341–349CrossRefPubMedGoogle Scholar
  39. 39.
    Kaufman J, Casanova JE, Riendl P, Schlueter DP (1989) Bronchial hyperreactivity and cough due to angiotensin-converting enzyme inhibitors. Chest 95:544–548CrossRefPubMedGoogle Scholar
  40. 40.
    Kidney JC, O’Halloran DJ, FitzGerald MX (1989) Captopril and lymphocytic alveolitis. BMJ 299:981PubMedCentralCrossRefPubMedGoogle Scholar
  41. 41.
    Kotlyar E, Keogh AM, Macdonald PS et al (2002) Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma. J Heart Lung Transplant 21:1290–1295CrossRefPubMedGoogle Scholar
  42. 42.
    Krum H, Ninio D, MacDonald P (2000) Baseline predictors of tolerability to carvedilol in patients with chronic heart failure. Heart 84:615–619PubMedCentralCrossRefPubMedGoogle Scholar
  43. 43.
    Lahousse L, Loth DW, Joos GF et al (2013) Statins, systemic inflammation and risk of death in COPD: the Rotterdam study. Pulm Pharmacol Ther 26:212–217CrossRefPubMedGoogle Scholar
  44. 44.
    Lee TM, Lin MS, Chang NC (2008) Usefulness of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin. Am J Cardiol 101:530–535CrossRefPubMedGoogle Scholar
  45. 45.
    Lipworth BJ, McDevitt DG, Struthers AD (1989) Prior treatment with diuretic augments the hypokalemic and electrocardiographic effects of inhaled albuterol. Am J Med 86:653–657CrossRefPubMedGoogle Scholar
  46. 46.
    Loke YK, Kwok CS, Singh S (2010) Risk of myocardial infarction and cardiovascular death associated with inhaled corticosteroids in COPD. Eur Respir J 35:1003–1021CrossRefPubMedGoogle Scholar
  47. 47.
    Lorenz J, Bals R, Magnussen H et al (2013) Expertentreffen obstruktive Atemwegserkrankungen: Kardiovaskuläre Aspekte der COPD. Pneumologie 67(12):663–675CrossRefPubMedGoogle Scholar
  48. 48.
    Lunde H, Hedner T, Samuelsson O et al (1994) Dyspnoea, asthma, and bronchospasm in relation to treatment with angiotensin converting enzyme inhibitors. BMJ 308:18–21PubMedCentralCrossRefPubMedGoogle Scholar
  49. 49.
    Mancini GB, Etminan M, Zhang B et al (2006) Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 47:2554–2560CrossRefPubMedGoogle Scholar
  50. 50.
    Martin WJ 2nd, Rosenow EC 3rd (1988) Amiodarone pulmonary toxicity. Recognition and pathogenesis (Part 1). Chest 93:1067–1075CrossRefPubMedGoogle Scholar
  51. 51.
    Martin WJ 2nd, Rosenow EC 3rd (1988) Amiodarone pulmonary toxicity. Recognition and pathogenesis (Part 2). Chest 93:1242–1248CrossRefPubMedGoogle Scholar
  52. 52.
    Martinez FJ, Curtis JL, Albert R (2008) Role of macrolide therapy in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 3:331–350PubMedCentralPubMedGoogle Scholar
  53. 53.
    Mason JW (1987) Amiodarone. N Engl J Med 316:455–466CrossRefPubMedGoogle Scholar
  54. 54.
    Matchar DB, McCrory DC, Orlando LA et al (2008) Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 148:16–29CrossRefPubMedGoogle Scholar
  55. 55.
    McGavin CR, Williams IP (1978) The effects of oral propranolol and metoprolol on lung function and exercise performance in chronic airways obstruction. Br J Dis Chest 72:327–332CrossRefPubMedGoogle Scholar
  56. 56.
    Merola JF (2012) Lupus-like syndromes related to drugs. In: Schur PH, Massarotti E (Eds) Lupus erythematosus: clinical evaluation and treatment. Springer, New York, S 211–221Google Scholar
  57. 57.
    Michele TM, Pinheiro S, Iyasu S (2010) The safety of tiotropium – the FDA’s conclusions. N Engl J Med 363:1097–1099CrossRefPubMedGoogle Scholar
  58. 58.
    Mosholder AD, Mathew J, Alexander JJ et al (2013) Cardiovascular risks with azithromycin and other antibacterial drugs. N Engl J Med 368:1665–1668CrossRefPubMedGoogle Scholar
  59. 59.
    Myers JL, Kennedy JI, Plumb VJ (1987) Amiodarone lung: pathologic findings in clinically toxic patients. Hum Pathol 18:349–354CrossRefPubMedGoogle Scholar
  60. 60.
    Nadrous HF, Ryu JH, Douglas WW et al (2004) Impact of angiotensin-converting enzyme inhibitors and statins on survival in idiopathic pulmonary fibrosis. Chest 126:438–446CrossRefPubMedGoogle Scholar
  61. 61.
    Ogale SS, Lee TA, Au DH et al (2010) Cardiovascular events associated with ipratropium bromide in COPD. Chest 137:13–19CrossRefPubMedGoogle Scholar
  62. 62.
    ONTARGET Investigators, Yusuf S, Teo KK et al (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358:1547–1559CrossRefGoogle Scholar
  63. 63.
    Patakas D, Maniki E, Tsara V, Dascalopoulou E (1987) Nifedipine treatment of patients with bronchial asthma. J Allergy Clin Immunol 79:959–963CrossRefPubMedGoogle Scholar
  64. 64.
    Pigakis K, Ferdoutsis M, Meletis G et al (2009) Pulmonary toxicity from cardiovascular drugs. Pneumon 22:75–84Google Scholar
  65. 65.
    Provencher S, Herve P, Jais X et al (2006) Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology 130:120–126CrossRefPubMedGoogle Scholar
  66. 66.
    Rabe KF (2012) Drug safety in COPD revisited: what is the number needed to analyze? Chest 142:271–274CrossRefPubMedGoogle Scholar
  67. 67.
    Ray WA, Murray KT, Hall K et al (2012) Azithromycin and the risk of cardiovascular death. N Engl J Med 366:1881–1890PubMedCentralCrossRefPubMedGoogle Scholar
  68. 68.
    Record NB Jr (1981) Acebutolol-induced pleuropulmonary lupus syndrome. Ann Intern Med 95:326–327CrossRefPubMedGoogle Scholar
  69. 69.
    Reiter J, Demirel N, Mendy A et al (2013) Macrolides for the long-term management of asthma – a meta-analysis of randomized clinical trials. Allergy 68:1040–1049CrossRefPubMedGoogle Scholar
  70. 70.
    Salpeter SS, Ormiston T, Salpeter E et al (2002) Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev (4):CD003566Google Scholar
  71. 71.
    Salpeter SR, Ormiston TM, Salpeter EE (2004) Cardiovascular effects of betaagonists in patients with asthma and COPD: a meta-analysis. Chest 125:2309–2321CrossRefPubMedGoogle Scholar
  72. 72.
    Schwartzstein RS, Fanta CH (1986) Orally administered nifedipine in chronic stable asthma. Comparison with an orally administered sympathomimetic. Am Rev Respir Dis 134:262–265PubMedGoogle Scholar
  73. 73.
    Shannon M (1999) Life-threatening events after theophylline overdose: a 10-year prospective analysis. Arch Intern Med 159:989–994CrossRefPubMedGoogle Scholar
  74. 74.
    Schatz PL, Mesologites D, Hyun J et al (1989) Captopril-induced hypersensitivity lung disease. An immune-complex-mediated phenomenon. Chest 95:685–687CrossRefPubMedGoogle Scholar
  75. 75.
    Short PM, Lipworth SI, Elder DH et al (2011) Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ 342:d2549PubMedCentralCrossRefPubMedGoogle Scholar
  76. 76.
    Singh S, Loke YK, Furberg CD (2008) Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 300:1439–1450CrossRefPubMedGoogle Scholar
  77. 77.
    Singh S, Loke YK, Enright PL, Furberg CD (2011) Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ 342:d3215PubMedCentralCrossRefPubMedGoogle Scholar
  78. 78.
    Suissa S, Assimes T, Ernst P (2003) Inhaled short acting beta agonist use in COPD and the risk of acute myocardial infarction. Thorax 58:43–46PubMedCentralCrossRefPubMedGoogle Scholar
  79. 79.
    Storey RF, Becker RC, Harrington RA et al (2011) Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy). Am J Cardiol 108:1542–1546CrossRefPubMedGoogle Scholar
  80. 80.
    Svanström H, Pasternak B, Hviid A (2013) Use of azithromycin and death from cardiovascular causes. N Engl J Med 368:1704–1712CrossRefPubMedGoogle Scholar
  81. 81.
    Swedberg K, Komajda M, Böhm M et al (2012) Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. J Am Coll Cardiol 59:1938–1945CrossRefPubMedGoogle Scholar
  82. 82.
    Tanawuttiwat T, Harindhanavudhi T, Hanif S, Sahloul MZ (2010) Amiodarone-induced alveolar haemorrhage: a rare complication of a common medication. Heart Lung Circ 19:435–437CrossRefPubMedGoogle Scholar
  83. 83.
    Toh S, Reichman ME, Houstoun M et al (2012) Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. Arch Intern Med 172:1582–1589CrossRefPubMedGoogle Scholar
  84. 84.
    Valle JM, Alvarez D, Antúnez J, Valdés L (1995) Bronchiolitis obliterans organizing pneumonia secondary to amiodarone: a rare aetiology. Eur Respir J 8:470–471CrossRefPubMedGoogle Scholar
  85. 85.
    Hooft CS van der, Heeringa J, Brusselle GG et al (2006) Corticosteroids and the risk of atrial fibrillation. Arch Intern Med 166:1016–1020CrossRefPubMedGoogle Scholar
  86. 86.
    Gestel YR van, Hoeks SE, Sin DD et al (2008) Effect of statin therapy on mortality in patients with peripheral arterial disease and comparison of those with versus without associated chronic obstructive pulmonary disease. Am J Cardiol 102:192–196CrossRefPubMedGoogle Scholar
  87. 87.
    Rijnsoever EW van, Kwee-Zuiderwijk WJ, Feenstra J (1998) Angioneurotic edema attributed to the use of losartan. Arch Intern Med 158:2063–2065CrossRefPubMedGoogle Scholar
  88. 88.
    Warnier MJ, Blom MT, Bardai A et al (2013) Increased risk of sudden cardiac arrest in obstructive pulmonary disease: a case-control study. PLoS One 8(6):e65638PubMedCentralCrossRefPubMedGoogle Scholar
  89. 89.
    Weinberger SE, Kaplan NM (2013) Treatment of hypertension in asthma and COPD. UpToDate. http://www.uptodate.com. Last update: Sept 09, 2013Google Scholar
  90. 90.
    White WB, Cooke GE, Kowey PR et al (2013) Cardiovascular safety in patients receiving roflumilast for the treatment of COPD. Chest 144(3):758–765CrossRefPubMedGoogle Scholar
  91. 91.
    Wilchesky M, Ernst P, Brophy JM et al (2012) Bronchodilator use and the risk of arrhythmia in COPD: part 1: Saskatchewan cohort study. Chest 142:298–304CrossRefPubMedGoogle Scholar
  92. 92.
    Wilchesky M, Ernst P, Brophy JM et al (2012) Bronchodilator use and the risk of arrhythmia in COPD: part 2: reassessment in the larger Quebec cohort. Chest 142:305–311CrossRefPubMedGoogle Scholar
  93. 93.
    Wong CS, Pavord ID, Williams J et al (1990) Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma. Lancet 336:1396–1399CrossRefPubMedGoogle Scholar
  94. 94.
    Worth H, Chung KF, Felser JM et al (2011) Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respir Med 105:571–579CrossRefPubMedGoogle Scholar
  95. 95.
    Zitnik RJ (1996) Drug-induced lung disease: antiarrhythmic agents. J Respir Dis 17:254–270Google Scholar

Copyright information

© Urban & Vogel 2014

Authors and Affiliations

  • S. Möhlenkamp
    • 1
  • G. Weinreich
    • 2
  • T. Neumann
    • 3
  • T. Voshaar
    • 4
  • H. Teschler
    • 2
  1. 1.Klinik für Kardiologie, Angiologie und Internistische IntensivmedizinKrankenhaus BethanienMoersDeutschland
  2. 2.Abteilung Pneumologie, Ruhrlandklinik, Westdeutsches LungenzentrumUniversitätsklinikum Essen, Universität Duisburg-EssenEssenDeutschland
  3. 3.Klinik für Kardiologie, Westdeutsches Herzzentrum EssenUniversitätsklinikum Essen, Universität Duisburg-EssenEssenDeutschland
  4. 4.Klinik für Pneumologie, Allergologie und SchlafmedizinKrankenhaus BethanienMoersDeutschland

Personalised recommendations